Search Result

Results for "

neuroinflammatory diseases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (2) Apoptosis (1) Cathepsin (1) Cholinesterase (ChE) (2) Endogenous Metabolite (2) Enterovirus (2) ERK (1) Free Fatty Acid Receptor (1) Histone Acetyltransferase (2) Interleukin Related (3) Isotope-Labeled Compounds (2) JNK (1) Monoamine Oxidase (4) NF-κB (1) NO Synthase (1) NOD-like Receptor (NLR) (4) p38 MAPK (2) Phosphodiesterase (PDE) (1) Potassium Channel (1) PPAR (4) Reactive Oxygen Species (ROS) (1) SphK (1) TNF Receptor (2) Toll-like Receptor (TLR) (1)
By Research Areas:	Cancer (2) Cardiovascular Disease (2) Infection (2) Inflammation/Immunology (17) Metabolic Disease (6) Neurological Disease (22)

By Targets:

Amyloid-β (2)

Apoptosis (1)

Cathepsin (1)

Cholinesterase (ChE) (2)

Endogenous Metabolite (2)

Enterovirus (2)

ERK (1)

Free Fatty Acid Receptor (1)

Histone Acetyltransferase (2)

Interleukin Related (3)

Isotope-Labeled Compounds (2)

JNK (1)

Monoamine Oxidase (4)

NF-κB (1)

NO Synthase (1)

NOD-like Receptor (NLR) (4)

p38 MAPK (2)

Phosphodiesterase (PDE) (1)

Potassium Channel (1)

PPAR (4)

Reactive Oxygen Species (ROS) (1)

SphK (1)

TNF Receptor (2)

Toll-like Receptor (TLR) (1)

By Research Areas:

Cancer (2)

Cardiovascular Disease (2)

Infection (2)

Inflammation/Immunology (17)

Metabolic Disease (6)

Neurological Disease (22)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-146195

MAPK-IN-1 2 Publications Verification	Toll-like Receptor (TLR) p38 MAPK JNK ERK Cholinesterase (ChE)	Neurological Disease Inflammation/Immunology
MAPK-IN-1 (Compound 2) is a MAPK signaling pathway inhibitor. MAPK-IN-1 exhibits AChE inhibitory activity with an IC₅₀ of 23.84 μM. MAPK-IN-1 shows anti-neuroinflammatory and neuroprotective activity and can be used for Alzheimer's disease research .

HY-P99025

Lebrikizumab 1 Publications Verification TNX-650	Interleukin Related	Neurological Disease Inflammation/Immunology
Lebrikizumab (TNX-650) is an IgG4 humanized anti-interleukin-13 (IL-13) mAb with anti-itch effects that specifically binds to IL-13 in a non-receptor binding domain and inhibits its function. Lebrikizumab inhibits the IL-13 driven Th2 inflammatory response and blocks the signaling of IL-4Rα/IL-13Rα1. Lebrikizumab can be used for the research of asthma, atopic dermatitis and neuroinflammatory diseases .

HY-146958

MAO-B-IN-8 1 Publications Verification	Monoamine Oxidase	Neurological Disease
MAO-B-IN-8 is a potent reversible MAO-B inhibitor and an inhibitor of microglial production of neuroinflammatory mediator. MAO-B-IN-8 can be used for neurodegenerative disease research .

HY-117727

Leriglitazone MIN-102; Hydroxypioglitazone	PPAR	Neurological Disease Metabolic Disease Inflammation/Immunology
Leriglitazone (MIN-102; Hydroxypioglitazone) is an orally active and a BBB-penetrable PPARγ agonist with an EC₅₀ of 9 μM. Leriglitazone, as a regulator of mitochondrial function, has neuroprotective, anti-inflammatory and antioxidant effects. Leriglitazone can be used in the study of neuroinflammatory and neurodegenerative diseases .

HY-150563

Neuroinflammatory-IN-2	Monoamine Oxidase Amyloid-β	Neurological Disease Inflammation/Immunology
Neuroinflammatory-IN-2 is a potent anti-neuroinflammatory agent with an IC₅₀ value of 10.30 μM for MAO-B, and 96.33% inhibition of Aβ_1-42 aggregation at 25 μM. Neuroinflammatory-IN-2 has neuroprotective activity in H₂O₂-induced PC-12 cell injury. Neuroinflammatory-IN-2 also has biometal chelating abilities, antioxidant activity, anti-neuroinflammatory activity and appropriate BBB permeability. Neuroinflammatory-IN-2 can be used for researching Alzheimer’s disease .

HY-N1818

Deoxysappanone B 3-Deoxysappanone B	p38 MAPK	Neurological Disease Inflammation/Immunology
Deoxysappanone B (3-Deoxysappanone B) is a homoisoflavone compound isolated from Caesalpinia sappan L (Lignum Sappan). Deoxysappanone B has anti-neuroinflammatory and neuroprotective effects and inhibits the production of neuroinflammatory mediators by blocking the IκB kinase (IKK)-NF-κB and p38/ERK MAPK pathways. Deoxysappanone B can be used in disease studies of neuritis and inflammation-related neurological damage .

HY-N15570

2-O-Methylatromentin	Interleukin Related TNF Receptor	Neurological Disease Inflammation/Immunology
2-O-Methylatromentin is an anti-neuroinflammatory agent. 2-O-Methylatromentin shows inhibitory activity on the production of pro-inflammatory cytokines TNF-α, IL-6 and IL-1β in Lipopolysaccharides (HY-D1056) (LPS) -induced BV-2 microglial cells. 2-O-Methylatromentin can be used for the study of neuroinflammatory related diseases .

HY-120152

SLP7111228	SphK	Inflammation/Immunology
SLP7111228 is a SphK1 inhibitor. SLP7111228 reduces LPS-induced TNFα and IL-1β production. SLP7111228 can be used in neuroinflammatory diseases research .

HY-P2710

Noxiustoxin	Potassium Channel	Neurological Disease Inflammation/Immunology
Noxiustoxin is a toxin from the venom of the Mexican scorpion Centruroides noxius which block voltage-dependent potassium channel (Kv1.3, IC₅₀ = 360 nM), and calcium-activated potassium channel. Noxiustoxin plays an important role in neuroinflammatory disease .

HY-117727A

Leriglitazone hydrochloride MIN-102 hydrochloride; Hydroxypioglitazone hydrochloride	PPAR	Neurological Disease Metabolic Disease Inflammation/Immunology
Leriglitazone (MIN-102; Hydroxypioglitazone) hydrochloride is an orally active and a BBB-penetrable PPARγ agonist with an EC₅₀ of 9 μM. Leriglitazone hydrochloride, as a regulator of mitochondrial function, has neuroprotective, anti-inflammatory and antioxidant effects. Leriglitazone hydrochloride can be used in the study of neuroinflammatory and neurodegenerative diseases .

HY-159944

PPARγ agonist 14	PPAR	Neurological Disease Metabolic Disease Inflammation/Immunology
PPARγ agonist 14 (compound 3) is a PPARy agonist (EC₅₀=2.4 μM) with anti-diabetic activity. PPARγ agonist 14 can improve intracellular glucose uptake, promote insulin release, and lower blood sugar. In addition, PPARγ agonist 14 also improves mitochondrial function, reduces oxidative stress, and inhibits inflammatory factors. PPARγ agonist 14 can be used in the study of neurodegenerative diseases, neuroinflammatory diseases, and other diseases .

HY-155126

LZWL02003	Reactive Oxygen Species (ROS)	Neurological Disease
LZWL02003 is an anti-neuroinflammatory agent. LZWL02003 has protective effect on MPP ⁺-induced neuronal damage, and reduces the expression of ROS. LZWL02003 improves cognition, memory, learning, and athletic ability in a Rotenone (HY-B1756)-induced PD rat model. LZWL02003 can be used for research of neurodegenerative disease .

HY-163695

NLRP3-IN-41	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-41 (compd S-9) is an orally active and brain-penetrant NLRP3 inhibitor with anti-inflammatory activities, anti-neuroinflammatory effect and without obvious cytotoxicity. NLRP3-IN-41 inhibits the priming and activation stages of the NLRP3 inflammasome and can be used for inflammasome-related diseases research .

HY-143245

Monoamine Oxidase B inhibitor 2	Monoamine Oxidase	Neurological Disease
Monoamine Oxidase B inhibitor 2 is a potent, reversible, orally active and selective monoamine oxidase B (MAO-B) inhibitor with an IC₅₀ of 1.33 nM. Monoamine Oxidase B inhibitor 2 has antioxidant and anti-neuroinflammatory activities. Monoamine Oxidase B inhibitor 2 can across the blood-brain barrier (BBB), and can be used for Parkinson’s disease study .

HY-143244

Monoamine Oxidase B inhibitor 1	Monoamine Oxidase	Neurological Disease
Monoamine Oxidase B inhibitor 1 is a potent, reversible, orally active and selective monoamine oxidase B (MAO-B) inhibitor with an IC₅₀ of 0.02 nM. Monoamine Oxidase B inhibitor 1 has antioxidant and anti-neuroinflammatory activities. Monoamine Oxidase B inhibitor 1 can across the blood-brain barrier (BBB), and can be used for Parkinson’s disease study .

HY-147846

AChE/PDE4-IN-1	Cholinesterase (ChE) Phosphodiesterase (PDE)	Neurological Disease
AChE/PDE4-IN-1 (compound 12c) is a potent and selective dual PDE4/AChE inhibitor, with IC₅₀s of 0.28 μM and 1.88 μM for AChE and PDE4D, respectively. AChE/PDE4-IN-1 exhibits anti-neuroinflammatory effect for the research of Alzheimer's disease .

HY-117727S

Leriglitazone-d4 MIN-102-d₄; Hydroxypioglitazone-d₄	Isotope-Labeled Compounds PPAR	Neurological Disease Metabolic Disease Inflammation/Immunology
Leriglitazone-d₄ (MIN-102-d₄; Hydroxypioglitazone-d₄) is deuterium labeled Leriglitazone. Leriglitazone is an orally active and a BBB-penetrable PPARγ agonist with an EC₅₀ of 9 μM. Leriglitazone, as a regulator of mitochondrial function, has neuroprotective, anti-inflammatory and antioxidant effects. Leriglitazone can be used in the study of neuroinflammatory and neurodegenerative diseases .

HY-156438

Ruvonoflast NT-0796	NOD-like Receptor (NLR) Interleukin Related	Neurological Disease
Ruvonoflast (NT-0796) is an orally active, selective and CNS-penetrant NLRP3 inflammasome inhibitor. Ruvonoflast inhibits IL-1β release in human PBMC cells with an IC₅₀ value of 0.32 nM. Ruvonoflast is an isopropyl ester that undergoes intracellular conversion to Ruvonoflast, the carboxylic acid active species. Ruvonoflast reverses high fat diet-induced obesity, systemic inflammation and astrogliosis in the diet-induced obesity mouse model. Ruvonoflast is promising for research of neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and amyotrophic lateral sclerosis .

HY-162093

Aβ1–42 aggregation inhibitor 2	Amyloid-β	Neurological Disease
Aβ1–42 aggregation inhibitor 2 (compound 7c) is a potent inhibitor of Aβ1-42 aggregation that plays an important role in Alzheimer's disease research. Aβ1–42 aggregation inhibitor 2 displays excellent antioxidant, metal ions chelating, oxidative stress alleviation, neuroprotective and anti-neuroinflammatory activities .

HY-W009081

Tricosanoic acid	Free Fatty Acid Receptor	Neurological Disease
Tricosanoic acid is an endogenous agonist of long-chain saturated fatty acids and free fatty acid receptor FFAR1, which can activate hair growth. Tricosanoic acid (C23:0) has the activity of improving cognitive function by regulating neuronal membrane fluidity, inhibiting neuroinflammatory response, participating in myelination and neuronal energy metabolism. Tricosanoic acid expression levels are low in the prefrontal cortex of Alzheimer's disease (AD) models; while better cognitive performance corresponds to higher serum concentration levels. Tricosanoic acid can be used as a biomarker for diseases related to cognitive decline .

HY-172977

FGA139	Cathepsin NO Synthase TNF Receptor	Neurological Disease Inflammation/Immunology
FGA139 is a cysteine proteases inhibitor with IC₅₀ values of 4.98/3.14 μM for cathepsin B/L. FGA139 reduces LPS-induced NO production in RAW264.7 cells and tumor necrosis factor (TNFα) levels in microglia, and has anti-oxidative stress and anti-inflammatory activities. FGA139 promotes the secretion of neuroprotective metabolites purine and linoleic acid by LPS-stimulated microglia. FGA139 can be used in neuroinflammatory diseases research .

HY-144765

NF-κB-IN-4 1 Publications Verification	NF-κB Apoptosis	Neurological Disease Inflammation/Immunology
NF-κB-IN-4 (compound 17) is a potent and BBB-penetrated NF-κB pathway inhibitor with blood brain barrier (BBB) permeability. NF-κB-IN-4 exhibits potential anti-neuroinflammatory activity with low toxicity. NF-κB-IN-4 can block the activation and phosphorylation of IκBα, reduce expression of NLRP3, and thus inhibit NF-κB activation. NF-κB-IN-4 can be used for neuroinflammation related diseases research .

HY-W019670

N4-Acetylcytidine 1 Publications Verification	Endogenous Metabolite Histone Acetyltransferase Enterovirus NOD-like Receptor (NLR)	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
N4-acetylcytidine (N4A) is an endogenous nucleoside metabolite from the degradation of tRNA. N4-Acetylcytidine is formed by N-acetyltransferase 10 and other enzymes. N4-acetylcytidine might sustain NLRP3 inflammasome activation via induction of HMGB1 expression and releasee. N4-Acetylcytidine modifies mRNA, tRNA and rRNA, affecting their stability, translation efficiency (such as enterovirus 71 RNA). N4-Acetylcytidine is used in the study of cancer, neuroinflammatory diseases, viral infections and obesity .

HY-W753593

N4-Acetylcytidine-13C5	Isotope-Labeled Compounds Enterovirus NOD-like Receptor (NLR) Histone Acetyltransferase Endogenous Metabolite	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
N4-Acetylcytidine- ¹³C₅ is the ¹³C-labeled N4-Acetylcytidine (HY-W019670). N4-acetylcytidine (N4A) is an endogenous nucleoside metabolite from the degradation of tRNA. N4-Acetylcytidine is formed by N-acetyltransferase 10 and other enzymes. N4-acetylcytidine might sustain NLRP3 inflammasome activation via induction of HMGB1 expression and releasee. N4-Acetylcytidine modifies mRNA, tRNA and rRNA, affecting their stability, translation efficiency (such as enterovirus 71 RNA). N4-Acetylcytidine is used in the study of cancer, neuroinflammatory diseases, viral infections and obesity .

Cat. No.	Product Name	Target	Research Area

HY-P10441A

S-palm P0(180–199) TFA 1 Publications Verification	Peptides	Inflammation/Immunology
S-palm P0(180–199) (TFA) is a peptide that enhances MHC II-restricted responses. S-palm P0(180–199) (TFA) can be used to establish models of chronic inflammatory demyelinating polyneuropathy (CIDP) and chronic experimental autoimmune neuritis (c-EAN). S-palm P0(180–199) (TFA) is used for studying autoimmune-mediated neuroinflammatory diseases .

HY-P5121A

γ-Fibrinogen 377-395 TFA	Peptides	Cardiovascular Disease
γ-Fibrinogen377-395 TFA is a fibrinogen-derived inhibitory peptide, as well as fibrinogen epitope. γ-Fibrinogen377-395 TFA blocks microglia activation and inhibits fibrin-Mac-1 interactions in vitro, and suppresses experimental autoimmune encephalomyelitis (EAE) in mice in vivo. γ-Fibrinogen377-395 TFA can be used for research in multiple sclerosis (MS), and other neuroinflammatory diseases associated with blood-brain barrier disruption and microglia activation .

HY-P2710

Noxiustoxin	Potassium Channel	Neurological Disease Inflammation/Immunology
Noxiustoxin is a toxin from the venom of the Mexican scorpion Centruroides noxius which block voltage-dependent potassium channel (Kv1.3, IC₅₀ = 360 nM), and calcium-activated potassium channel. Noxiustoxin plays an important role in neuroinflammatory disease .

HY-P5121

γ-Fibrinogen 377-395	Peptides	Cardiovascular Disease
γ-Fibrinogen377-395 is a fibrinogen-derived inhibitory peptide, as well as fibrinogen epitope. γ-Fibrinogen377-395 blocks microglia activation and inhibits fibrin-Mac-1 interactions in vitro, and suppresses experimental autoimmune encephalomyelitis (EAE) in mice in vivo. γ-Fibrinogen377-395 can be used for research in multiple sclerosis (MS), and other neuroinflammatory diseases associated with blood-brain barrier disruption and microglia activation .

Cat. No.	Product Name	Target	Research Area

HY-P99025

Lebrikizumab 1 Publications Verification TNX-650	Interleukin Related	Neurological Disease Inflammation/Immunology
Lebrikizumab (TNX-650) is an IgG4 humanized anti-interleukin-13 (IL-13) mAb with anti-itch effects that specifically binds to IL-13 in a non-receptor binding domain and inhibits its function. Lebrikizumab inhibits the IL-13 driven Th2 inflammatory response and blocks the signaling of IL-4Rα/IL-13Rα1. Lebrikizumab can be used for the research of asthma, atopic dermatitis and neuroinflammatory diseases .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W009081

Tricosanoic acid	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Free Fatty Acid Receptor
Tricosanoic acid is an endogenous agonist of long-chain saturated fatty acids and free fatty acid receptor FFAR1, which can activate hair growth. Tricosanoic acid (C23:0) has the activity of improving cognitive function by regulating neuronal membrane fluidity, inhibiting neuroinflammatory response, participating in myelination and neuronal energy metabolism. Tricosanoic acid expression levels are low in the prefrontal cortex of Alzheimer's disease (AD) models; while better cognitive performance corresponds to higher serum concentration levels. Tricosanoic acid can be used as a biomarker for diseases related to cognitive decline .

HY-W019670

N4-Acetylcytidine 1 Publications Verification	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite Histone Acetyltransferase Enterovirus NOD-like Receptor (NLR)
N4-acetylcytidine (N4A) is an endogenous nucleoside metabolite from the degradation of tRNA. N4-Acetylcytidine is formed by N-acetyltransferase 10 and other enzymes. N4-acetylcytidine might sustain NLRP3 inflammasome activation via induction of HMGB1 expression and releasee. N4-Acetylcytidine modifies mRNA, tRNA and rRNA, affecting their stability, translation efficiency (such as enterovirus 71 RNA). N4-Acetylcytidine is used in the study of cancer, neuroinflammatory diseases, viral infections and obesity .

HY-N1818

Deoxysappanone B 3-Deoxysappanone B	Structural Classification Leguminosae Caesalpinia sappan L. Source classification Phenols Polyphenols Plants	p38 MAPK
Deoxysappanone B (3-Deoxysappanone B) is a homoisoflavone compound isolated from Caesalpinia sappan L (Lignum Sappan). Deoxysappanone B has anti-neuroinflammatory and neuroprotective effects and inhibits the production of neuroinflammatory mediators by blocking the IκB kinase (IKK)-NF-κB and p38/ERK MAPK pathways. Deoxysappanone B can be used in disease studies of neuritis and inflammation-related neurological damage .

HY-N15570

2-O-Methylatromentin	Structural Classification Microorganisms Source classification Phenols Polyphenols	Interleukin Related TNF Receptor
2-O-Methylatromentin is an anti-neuroinflammatory agent. 2-O-Methylatromentin shows inhibitory activity on the production of pro-inflammatory cytokines TNF-α, IL-6 and IL-1β in Lipopolysaccharides (HY-D1056) (LPS) -induced BV-2 microglial cells. 2-O-Methylatromentin can be used for the study of neuroinflammatory related diseases .

Cat. No.	Product Name	Chemical Structure

HY-W753593

N4-Acetylcytidine-13C5
N4-Acetylcytidine- ¹³C₅ is the ¹³C-labeled N4-Acetylcytidine (HY-W019670). N4-acetylcytidine (N4A) is an endogenous nucleoside metabolite from the degradation of tRNA. N4-Acetylcytidine is formed by N-acetyltransferase 10 and other enzymes. N4-acetylcytidine might sustain NLRP3 inflammasome activation via induction of HMGB1 expression and releasee. N4-Acetylcytidine modifies mRNA, tRNA and rRNA, affecting their stability, translation efficiency (such as enterovirus 71 RNA). N4-Acetylcytidine is used in the study of cancer, neuroinflammatory diseases, viral infections and obesity .

N4-Acetylcytidine-13C5

N4-Acetylcytidine- ¹³C₅ is the ¹³C-labeled N4-Acetylcytidine (HY-W019670). N4-acetylcytidine (N4A) is an endogenous nucleoside metabolite from the degradation of tRNA. N4-Acetylcytidine is formed by N-acetyltransferase 10 and other enzymes. N4-acetylcytidine might sustain NLRP3 inflammasome activation via induction of HMGB1 expression and releasee. N4-Acetylcytidine modifies mRNA, tRNA and rRNA, affecting their stability, translation efficiency (such as enterovirus 71 RNA). N4-Acetylcytidine is used in the study of cancer, neuroinflammatory diseases, viral infections and obesity .

HY-117727S

Leriglitazone-d4
Leriglitazone-d₄ (MIN-102-d₄; Hydroxypioglitazone-d₄) is deuterium labeled Leriglitazone. Leriglitazone is an orally active and a BBB-penetrable PPARγ agonist with an EC₅₀ of 9 μM. Leriglitazone, as a regulator of mitochondrial function, has neuroprotective, anti-inflammatory and antioxidant effects. Leriglitazone can be used in the study of neuroinflammatory and neurodegenerative diseases .

Leriglitazone-d4

Leriglitazone-d₄ (MIN-102-d₄; Hydroxypioglitazone-d₄) is deuterium labeled Leriglitazone. Leriglitazone is an orally active and a BBB-penetrable PPARγ agonist with an EC₅₀ of 9 μM. Leriglitazone, as a regulator of mitochondrial function, has neuroprotective, anti-inflammatory and antioxidant effects. Leriglitazone can be used in the study of neuroinflammatory and neurodegenerative diseases .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks